Dianthus Therapeutics vs Shattuck Labs
DNTH and STTK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DNTH and STTK compare
Dianthus Therapeutics is the larger company, worth 9.9 times as much as Shattuck Labs ($5.0B against $507M).
Shattuck Labs scores higher on the StockData Score (8 against 7 for Dianthus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DNTH | STTK |
|---|---|---|
| Size and price | ||
| Market cap | $5.0B | $507M |
| Share price | $89.30 | $5.05 |
| Change, 1 year | 144% | 167% |
| Change, 5 years | −16.6% | −46.3% |
| Beta (5Y) | 1.44 | 1.63 |
| Employees | 92 | 40 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 4.0× | 2.6× (better) |
| Growth | ||
| Revenue growth (TTM) | – | −100% |
| Revenue growth, 5Y average | – | −36.8% |
| Profitability | ||
| Return on equity | −22.6% (better) | −47.2% |
| Return on invested capital | −22.2% (better) | −2531% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 30.02 (better) | 15.80 |
| Altman Z-score | 85.71 (better) | 17.92 |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | −0.01% (better) | −19.9% |
| Shareholder yield | −0.01% (better) | −19.9% |
| Ownership | ||
| Held by institutions | 118% | 83.5% |
| Held by insiders | 9.1% | 24.1% |
| Insider net buying, 12 months | −$63.8M | −$342K (better) |
| Short interest, % of float | 18.2% | 14.1% |
Go deeper
- DNTH stock overview
- DNTH income statement
- DNTH valuation and score
- STTK stock overview
- STTK income statement
- STTK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.